March 30, 2020
Chagas Disease Drugs

Chagas Disease Drugs Market | Rising number of travelling and migrating individuals is the prime factor driving the growth

 Americas and Europe Chagas disease drugs market, expanding at a CAGR of 1.5% from 2017 to 2025.

Market Insights

Chagas disease, also known as US trypanosomiasis, is an inflammatory, infectious disease caused by the parasite Trypanosoma cruzi. It is estimated that the market for Chagas disease drugs will show slow growth over the forecast period due to an increase in human migration, travel from the endemic region to non-endemic regions and an increase in health awareness among the general population. For the purpose of the study, the market for Chagas disease drugs is segmented on the basis of the drug type, such as Benznidazole and Nifurtimox. It is noted that Benznidazole is a major revenue-contributing segment in the base year 2016 due to its safety and efficacy and its use as a first-line treatment option. Benznidazole is the first and only drug approved for the treatment of Chagas disease in the United States. Previously, Benznidazole was available through the CDC, but was not approved by the FDA. Benznidazole approval by the FDA is a milestone in the United States and a global response to addressing the burden of Chagas disease.

Access sample copy here:

However, shortage in drug supply, limited accessibility and lack of guidelines supporting implementation are affecting the growth of chagas disease drugs market. North America chagas disease drugs market is expected to show the fastest growth over the forecast period, with particular lead by the United States. Increase in number of migration from endemic countries to United States would drive the market growth in North America.

Market Competition Assessment:

There are a limited number of chagas disease drugs manufacturers present in market such as Bayer AG., F. Hoffmann-La Roche Ltd., Humanigen, Inc., Johnson & Johnson, KaloBios Pharmaceuticals, Inc., Savant Neglected Diseases, LLC and other.

Key Market Movements:

Factors such as rising immigration from endemic countries to non-endemic region and rising healthcare awareness among the general population in developing region would primarily drive the growth of Americas and Europe chagas disease drugs market.  

Access sample copy here:

Leave a Reply

Your email address will not be published. Required fields are marked *